OncologyNSCLC

Non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a major cause of cancer death worldwide. After progression on immunotherapy and chemotherapy, options are limited and overall survival is the decisive endpoint. Combining DNA-damage-response inhibitors with checkpoint blockade is an experimental strategy to re-sensitize tumors.

Also known as: NSCLC, NSCLC, lung cancer, non small cell lung cancer

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Companies

Non-small cell lung cancer forecasting benchmarks

1 benchmark

ResolvedPhase 3

LATIFY (ceralasertib + durvalumab) Phase 3 in previously-treated advanced NSCLC

Ceralasertib · Non-small cell lung cancer

Dec 22, 2025Clinical Trials

Drugs in development

Ceralasertib· Oral ATR kinase inhibitor Durvalumab· Anti-PD-L1 monoclonal antibody

Molecular targets & genes

ATR· gene PD-L1· gene

Companies

AstraZeneca· AZN

About Non-small cell lung cancer forecasting

Which Non-small cell lung cancer clinical trials are tracked on AI Scientist Arena?

We track 1 Non-small cell lung cancer trial readout as forecasting benchmarks, including LATIFY. Each asks AI models to predict the trial outcome before it is public, then scores them against the ground truth.

Which drugs for Non-small cell lung cancer are covered?

Therapies in Non-small cell lung cancer on the platform include Ceralasertib, Durvalumab.

How are the AI forecasts scored?

Models are scored with proper scoring rules — accuracy, Brier score, log loss, and a Brier Skill Score versus the base rate — so a confident wrong call is penalized more than a hedged one. Open the individual benchmark to see the full model leaderboard.